Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?

Clin Appl Thromb Hemost. 2021 Jan-Dec:27:10760296211033906. doi: 10.1177/10760296211033906.

Patrick Van Dreden¹, Jawed Fareed^{2

3}, Ismail Elalamy^{4

5

6}, Grigoris Gerotziafas^{4

5}

¹ Sorbonne Université, INSERM, UMR_S 938, Research Group « Cancer, Biology and Therapeutics », Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France.
² Clinical Research Department, Diagnostica Stago, Gennevilliers, France.
³ Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
⁴ Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
⁵ Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France.
⁶ Department of Obstetrics and Gynecology, I M Sechenov First Moscow State Medical University, Moscow, Russia.

No abstract available

Keywords: COVID-19; mRNA; vaccine.

Publication types